Spots Global Cancer Trial Database for The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

Official Title: The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy

Study ID: NCT01248000

Conditions

Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

Interventions

FDG-PET

Study Description

Brief Summary: Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.

Detailed Description: